On September 30, 2019 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer (Press release, Sangamo Therapeutics, SEP 30, 2019, View Source [SID1234539988]). Dr. Cockroft will oversee all clinical development activities and operations and will report to the Executive Vice President of Research and Development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Bettina brings over 20 years of clinical development experience, having worked across multiple therapeutic areas and leading programs in several countries," said Adrian Woolfson, BM., B.Ch., Ph.D., Executive Vice President, Research and Development. "This is an important time to welcome Bettina to Sangamo, as we expect a steady flow of readouts from our ongoing clinical trials and expect to initiate additional trials in the coming year. We look forward to Bettina’s contributions and believe she will be a key player in helping us realize our mission of translating our groundbreaking science into genomic medicines that transform patients’ lives."

Dr. Cockroft has 23 years of experience in the biopharmaceutical industry and joins Sangamo from Cytokinetics, Inc., where she was a member of the senior leadership team responsible for clinical development of fast skeletal muscle troponin activators in diseases such as Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy. Before that, Dr. Cockroft served as Chief Medical Officer of Auris Medical AG, where she led and grew the clinical development team responsible for two Phase 3 programs. Dr. Cockroft also held roles of increasing responsibility at Merck Serono S.A., Novartis Consumer Health and Menarini Ricerche earlier in her career.

Dr. Cockroft earned her MBA at MIT Sloan School of Management and her MD from the University of Genoa.

On September 30, 2019 Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder, Executive Vice President and Chief Scientific Officer, will present a corporate overview at the Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:40 a.m. EDT in New York (Press release, Celldex Therapeutics, SEP 30, 2019, View Source [SID1234539983]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for seven days following the event.

On September 30, 2019 Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer reported that as a result of its work with scientists from Janssen Research & Development, LLC, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has elected to exercise a commercial option to license and advance an undisclosed multispecific product for development in an oncology indication (Press release, TeneoBio, SEP 30, 2019, View Source [SID1234539982]). Under the terms of the collaboration agreement, which was first announced in Q3 of 2018, Janssen will receive exclusive global licensing rights to the multispecific product for clinical development and commercialization. Teneobio will receive a milestone payment from Janssen for the commercial license and is eligible for additional development and commercial milestones as well as royalties on world-wide net sales of the multispecific product.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Omid Vafa, CBO of Teneobio, Inc., added, "We are very pleased with the outcome of our collaboration with the Janssen R&D oncology team. The rapid advance of our program from discovery to preclinical proof-of-concept in less than a year and a half is a testament to Teneobio’s technology platforms and speed to enable drug discovery and to deliver. Janssen’s collaborative spirit allowed both teams to rapidly advance the multispecific antibody lead clinical candidate beyond preclinical proof-of-concept. We are eager to advance this asset to clinical stage, and Janssen’s deep expertise in the oncology space is a real advantage."

On September 30, 2019, Delcath Systems, Inc (the "Company") and holders of a majority of the Company’s Series E and Series E-1 Convertible Preferred Stock entered into an amendment to those certain registration rights agreements, dated as of July 11, 2019 (effective as of July 15, 2019) (the "July Registration Rights Agreement") and August 15, 2019 (the "August Registration Rights Agreement"), between the Company and the holders signatory thereto (the "Amendment") (Filing, 8-K, Delcath Systems, SEP 30, 2019, View Source [SID1234539977]). The Amendment extends the applicable deadline for having a registration statement declared effective by the Securities and Exchange Commission (the "SEC") under certain circumstances from 75 days to 120 days following the date of the July Registration Rights Agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing description of certain terms contained in the Amendment does not purport to be complete and is qualified in its entirety by reference to: (i) the copy of the Amendment filed as Exhibit 10.1 to this Current Report on Form 8-K, (ii) the copy of the Form of Registration Rights Agreement between the Company and each other party a signatory thereto filed as Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on July 11, 2019 and (iii) the copy of the Form of Registration Rights Agreement between the Company and each other party a signatory thereto filed as Exhibit 4.2 to the Current Report on Form 8-K filed with the SEC on August 16, 2019.

On September 30, 2019 ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, and Bukwang Pharmaceutical (KRX:003000), a leading R&D focused Korean pharmaceutical company, reported that they have established a new joint venture to develop preclinical aryl hydrocarbon receptor (AhR) antagonists from ASLAN’s early stage pipeline (Press release, ASLAN Pharmaceuticals, SEP 30, 2019, View Source [SID1234539975]). The independent company, JAGUAHR Therapeutics, will focus on developing new immuno-oncology therapeutics for global markets targeting the AhR pathway and will be based in Singapore.

Under the terms of the agreement, ASLAN will transfer the global rights to all of the assets related to AhR technology, originally discovered and developed by ASLAN and its collaborator Dr Mark Graham, into JAGUAHR. Bukwang will invest US$5 million in JAGUAHR in two tranches to fund the development of the assets, identify a lead development compound and file an Investigational New Drug application.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: "The launch of JAGUAHR Therapeutics is an important step by ASLAN to realise the value of our early stage assets and advance the development of our AhR antagonist technology at a time when focus is shifting towards AhR antagonists as a hot new area in immuno-oncology. Bukwang has a strong track record of achievement in the pharma business and creating this spinout together allows both companies to quickly progress these exciting compounds and potentially provide novel clinical assets to enrich the ASLAN pipeline. We look forward to working with the Bukwang team as we focus on identifying JAGUAHR’s first drug candidate."

Dr Hee-Won Yoo, Chief Executive Officer, Bukwang Pharmaceutical, added: ""We are impressed and delighted to partner with ASLAN to establish JAGUAHR Therapeutics. Bukwang has a strong heritage in R&D and this agreement is aligned to our strategy to strengthen our innovative development pipeline and broaden early access to promising technology for treating conditions with unmet needs. We are very excited as the AhR antagonists program further marks Bukwang’s formal participation in the immuno-oncology arena. We look forward to working together with ASLAN to progress these novel immuno-oncology compounds into clinical development in oncology."

AhR is a druggable transcription factor that acts as a master regulator of the immune system. The enzymes IDO1, IDO2 and TDO are frequently overexpressed in numerous tumour types and convert tryptophan into kynurenine (KYN) in the tumour microenvironment. KYN is then actively transported into dendritic cells and effector T-cells that are mobilised to detect and kill tumour cells. KYN signalling via AhR in these cell types converts them into regulatory T-cells, suppressing the immune system and preventing it from attacking tumour cells. Research has demonstrated

that the unique advantages of AhR antagonists include broadly inhibiting the signalling of all AhR ligands1 produced by any enzyme that metabolises tryptophan, and robust activation of the immune response to kill cancer cells.

Ends

Media and IR contacts

For ASLAN Pharmaceuticals Limited

Emma Thompson

Spurwing Communications

Tel: +65 6571 2021

Email: [email protected]

Robert Uhl

Westwicke Partners

Tel: +1 858 356 5932

Email: [email protected]

For Bukwang Pharmaceutical Co., Ltd.

Riswanto

Global Business Development

Tel: +82-2-828-8072

Email: [email protected]